TransMedics Group Sees Unusually High Options Volume (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) saw some unusual options trading on Monday. Stock investors purchased 15,600 put options on the company. This is an increase of 603% compared to the typical volume of 2,219 put options.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd bought a new stake in TransMedics Group during the 3rd quarter worth about $29,000. Optiver Holding B.V. raised its holdings in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the last quarter. North Star Investment Management Corp. bought a new stake in TransMedics Group during the 1st quarter worth about $30,000. Ascentis Independent Advisors bought a new stake in TransMedics Group during the 1st quarter worth about $30,000. Finally, Allworth Financial LP raised its holdings in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TMDX shares. Piper Sandler cut their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. UBS Group reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Canaccord Genuity Group cut their price objective on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC cut their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Hold” and an average price target of $134.00.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded up $1.95 during trading on Monday, reaching $74.86. The company’s stock had a trading volume of 556,212 shares, compared to its average volume of 1,092,630. The stock has a 50-day moving average price of $86.20 and a two-hundred day moving average price of $115.01. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group has a one year low of $60.10 and a one year high of $156.00. The stock has a market capitalization of $2.59 billion, a P/E ratio of 17.05 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 earnings per share. As a group, sell-side analysts anticipate that TransMedics Group will post 1.98 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.